Exhibit 99.1

Facilitating Life Science Innovations to Serve Unmet Medical Needs NASDAQ GLOBAL MARKET: APM CORPORATE PRESENTATION

This document includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 . For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward - looking statements . In some cases, you can identify forward - looking statements by terms suc h as “may,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential,” or “continue,” or the negative of these terms or other similar expressions . Aptorum Group has based these forward - looking statements, which include statements regarding projected timelines for application submissions, trials and commercialization and market potential of related products, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations . These forward - looking statements speak only as of the date of this document and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company’s anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group’s Form 20 - F and other filings that Aptorum Group may make with the SEC in the future . As a result, the projections included in such forward - looking statements are subject to change and results may differ materially from those disclosed herein . Aptorum Group assumes no obligation to update any forward - looking statements contained in this document as a result of new information, future events or otherwise . 2 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited Disclaimer

Company Information • Established in 2010, Aptorum is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology, auto - immune and infectious diseases. • Business Strategy : from Discovery to Phase II Proof - of - Concept (PoC). • Markets and Regulatory : targeted for clinical and market approval by US FDA, China NMPA, Europe EMA and regulatory authorities in other major countries. • IPO : listed on NASDAQ Global Market (ticker symbol: APM) since December 18, 2018 and cross - listed on Euronext Paris (ticker symbol: APM) since July 24, 2020. • Company’s principal executive office is based in London, United Kingdom • Development of key products in partnership with North America based CROs (US and Canada), including GLP studies, GMP manufacturing and clinical trials coordination. • Completion of Phase I clinical trials for 2 therapeutic drugs ALS - 4 (MRSA) and SACT - 1 (Neuroblastoma), Clinical validation phase for RPIDD (liquid biopsy infectious disease molecular diagnostics) and Commercialization stage for NLS - 2 (Nativuswell), a Women’s menopause supplement product. About Aptorum Group 3 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

Directors, Management and Significant Employees Leadership Mr. Ian HUEN Founder, Chief Executive Officer and Executive Director 4 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited • Over 18 years in global asset management; • US healthcare equity research analyst at Janus Henderson Group; • Trustee board member of Dr. Stanley Ho Medical Development Foundation; • CFA, Princeton University, U.S. (Econ) DR. Clark CHENG Chief Medical Officer and Executive Director • Almost 10 years working in Raffles Medical Group as Operations Director and Deputy General Manager ; • Received medical training at the University College London in 2005 & obtained membership of the Royal College of Surgeons of Edinburgh in 2009; • MBA, University of Iowa, U.S. MR. Darren LUI President and Executive Director • Over 15 years in global capital market; • Director of Structured Capital Markets at Barclays Capital.; • Chartered Accountant (ICAS), Chartered Financial Analyst & Associate of Chartered Institute of Securities & Investments (UK); • First - Class Honors from Imperial College (Biochemistry) MISS Sabrina KHAN Chief Financial Officer • Over 10 years serving US & Asian healthcare companies; • Extensive experience in business development, restructuring, US & Asian IPO, and M&A deals; • Chartered Accountant at Ernst & Young LLP; • Advanced China Certified Taxation Consultant; • CPA, University of Hong Kong (BBA(Acc & Fin)) DR. Thomas LEE Wai Yip Head of Research and Development • Former Assistant Professor at The Chinese University of Hong Kong (CUHK) specialized in drug delivery and formulation development; • 10 years from Novartis & Celgene; • B.Pharm.(Hons), CUHK; Ph.D. in Pharmaceutical Sciences (Drug Delivery), the University of Wisconsin - Madison PROFESSOR Douglas ARNER Kerry Holdings Professor in Law, HKU DR. MIRKO SCHERER CEO of CoFeS China and Ex Head of TVM Asia DR. Justin WU COO of CUHK Medical Centre MR . Charles BATHURST Founder of Summerhill Advisors Limited Independent Non - Executive Directors

Aptorum Team Consultants and Advisors to Aptorum Group and Subsidiaries MR. William WEISS Consultant 5 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited • Currently Director of Preclinical Service and Instructor of Pharmaceutical Sciences, College of Pharmacy, University of North Texas; • 38 years of experience in drug discovery and development of antimicrobials including antibiotics, antivirals and antifungals; • Former Director of Cumbre Pharmaceuticals Inc; • Former Group Leader at Wyeth for 17 years; • Formerly employed at Schering - Plough for 7 years; • BSc in Microbiology from Rutgers University; MSc in Microbiology from Penn State University and Fairleigh Dickinson University DR. Robbie MAJZNER Advisor • Assistant professor of Pediatrics (Hematology/Oncology) at the Stanford University Medical Center; • Completed residency training in pediatrics and fellowship training in pediatric hematology - oncology; • Board certified in pediatrics and pediatric hematology - oncology; • M.D., Harvard Medical School DR. Kira SHEINERMAN Senior Strategic Consultant • Co - Founder, CEO and Executive Director of DiamiR Biosciences; • Serves as a Managing Director, Healthcare Investment Banking at H.C. Wainwright & Co.; • Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine in New York; • Honors MBA from Zicklin School of Business, Baruch College, City University of New York DR. Keith CHAN Consultant • Adjunct professor and advisor at the Research Center for Drug Discovery, National Yang Ming University in Taipei; • Former Division Director of Office of Generic Drugs, US FDA; • Co - founder of Globomax LLC; • Formerly employed at Ciba - Geigy DR . Nishant AGRAWAL Senior Clinical Advisor • Professor of Surgery, School of Medicine, University of Chicago; • Former Asso. Professor at Johns Hopkins University; • M.D., Johns Hopkins University School of Medicine DR. Lawrence BAUM Senior Scientific Advisor • Asso. Professor, School of Pharmacy, The Chinese University of Hong Kong; • Research Officer, Faculty of Medicine, The University of Hong Kong; • Ph.D. in Neurosciences, UC San Diego DR. Francis SZELE Senior Scientific Advisor • Asso. Professor, Department of Physiology, Anatomy & Genetics, University of Oxford; • Asst. Professor, Subventricular Zone, Northwestern University; • Ph.D. in Biology, The University of Pennsylvania, U.S.

Clinical Stage Programs Project Candidate / Modality Indication Development Stage Ac ೦ cule's Series Target id e n t i f i ca t io n & Selection Lead D i sc o v er y Lead Op t i m i z a t io n I N D ( O r I N D e qui v a l e n t Enabling) C lini ca l T r i a l Application S ub m i ss io n Phase I P h as e I I / II I ALS - 4 Small molecule Treatment of bacterial infec ೦ ons caused by Staphylococcus aureus including MRSA SACT’s Series C o m pu t a t ion a l Discovery I n V i t r o Validation E x i s t in g P hI/I I C lini ca l S a f e ty Data 1 I n V i v o Validation I N D P re p ara t io n & Submission Phase I P h as e I b / II a SACT - 1 Repurposed small molecule Neuroblastoma and other poten ೦ al cancer types RPIDD Development and Experimentation Product Optimization C lini ca l v a lid a t io n & P re - C o mmerc i a li z a t io n p re p ara t io n C o mmerc i a l - ization RPIDD Liquid biopsy rapid pathogen diagnos ೦ cs Pathogen molecular diagnos ೦ cs Project Modality Target Customer Formulation Commercialization and Distribution N a ೦ vu s W e ll® DOI (NLS - 2) 2 Dietary Supplement Women undergoing menopause 1. Refers to the drug’s existing Phase I/II safety data previously conducted by a third party. Does not refer to clinical trials conducted by Aptorum. 2. Commercialization in the UK, Hong Kong and EU in 2022. Targeted for US in 2023 subject to registration. Current Progress of Leading Pipeline Clinical and Discovery Programs 6 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

Discovery Stage Programs Project Candidate / Modality Indication Development Stage SACT’s Series C o m pu t a t ion a l Discovery I n V i t r o Validation E x i s t in g P hI/I I C lini ca l S a f e ty Data 1 I n V i v o Validation I N D P re p ara t io n & Submission Phase I P h as e I b / II a SACT - COV19 Repurposed small molecule Coronavirus Disease 2019 (COVID - 19) SACT - 2 Repurposed small molecule To be disclosed SACT - 3 Repurposed small molecule To be disclosed Ac ೦ cule’s Series Target id e n t i f i ca t io n & Selection Lead D i sc o v er y Lead Op t i m i z a t io n I N D ( O r I N D e qui v a l e n t Enabling) C lini ca l T r i a l Application S ub m i ss io n Phase I P h as e I I / II I ALS - 1 Small molecule Treatment of viral infec ೦ ons caused by influenza virus A ALS - 2/3 Small molecule Treatment of gram+ve bacterial infec ೦ ons Discovery Stage DLS - 1+2 Small molecule & Degraders NSCLC with muta ೦ on DLS - 3 Small molecule Autoimmune 1. Refers to the drug’s existing Phase I/II safety data previously conducted by a third party. Does not refer to clinical trials conducted by Aptorum. Current Progress of Leading Pipeline Clinical and Discovery Programs 7 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

• Additional novel anti - virulent, non - bactericidal approach therapeutics targeting Gram - positive bacteria 1 • In discovery/lead optimization stage and generating good traction towards doing IND - enabling studies 1 • Aptorum's lead program ALS - 4 is an anti - virulent, non - bactericidal drug candidate for Staphylococcus aureus infections including MRSA 1 • Unlike all major treatments currently on the market, ALS - 4 is an orally administered anti - virulent molecule using a non - bactericidal approach 1 to potentially reduce significant risks of developing S. aureus resistance • Phase I clinical study in North America completed in 2021. • A unique antiviral therapeutic against Influenza A with a more upstream target that is shown to be more effective than Tamiflu® in vitro 1 • Viral resistance to Tamiflu and other neuraminidase inhibitors has risen rapidly in recent years 2 • Has a distinct mechanism of action compared with Tamiflu® and Xofluza® 1,3 ALS - 4 is an anti - virulent, non - bactericidal drug candidate for Staphylococcus aureus infections including MRSA 1 V alue of the glo b al M R SA drugs mar k e t in 2016 2 30 % US $ 2 . 9 bn 3 . 2 % Mor t a l i t y r a t e of p a tien t s C A GR glo b al M R SA drugs w i t h S. au r eus mar k e t bacteremia (2017 - 2025) 2 MARKE T SIZE LEAD PROJECTS: ALS - 4 ALS - 2/ALS - 3 ALS - 1 1. Based on Aptorum's internal tests/experimentation and has not yet been verified by clinical trials or third party testing; 2. Influenza Antiviral Medications: Summary for Clinicians. CDC. https://www.cdc.gov/flu/pr o fessionals/antivirals/ summary - clinicians.htm; 3. Nat Biotechnol. 2010 Jun;28(6):600 - 5 Executive Summary: Acticule Projects 8 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

• Generic antibiotic that is the most frequently prescribed for MRSA - suspected infections 1,2 • After >60 years 3 of clinical use, its use against S. aureus is becoming limited. Vancomycin has been shown to have slow bactericidal activity, poor anti - staphylococcal activity, poor tissue penetration, and high rates of infection relapse 4,5,6,7,8,9 • The shortcomings of Vancomycin have been compounded since the discovery of vancomycin - resistant S. aureus (VRSA) in 2002 10 • Vancomycin is not orally bioavailable and must be administered intravenously in order to treat systemic infections 11,12 . Oral vancomycin is only effective for treating local intestinal infections 13 . Therefore, for MRSA - suspected infections oral vancomycin is only indicated for the treatment of pseudomembranous colitis 14 ALS - 4: Stand Alone or as Combination Therapy with Antibiotics (e.g. Vancomycin) • ALS - 4 demonstrated efficacy both on a standalone basis and combination basis (with Vancomycin) 15,17 • ALS - 4 can potentially complement other bactericidal antibiotics as well, therefore ALS - 4 is not a direct competitor of antibiotics • Synergistic effects of other drugs with vancomycin against MRSA has been demonstrated previously with β - lactam antibiotics and vancomycin 16 1. “Companies Take Aim at MRSA Infections” P T. 2016 Feb; 41(2): 126 – 128; 2. Clin Infect Dis. 2011 Feb 1;52(3):e18 - 55; 3. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S5 - 12; 4. Antimicrob Agents Chemother. 2008 Jan;52(1):192 - 7; 5. Clin Infect Dis. 2007 Jan 15;44(2):190 - 6; 6. Clin Infect Dis. 2007 Sep 1;45(5):601 - 8; 7. J Clin Microbiol. 2011 Oct;49(10):3669 - 72; 8. Clin Infect Dis. 2007 Sep 15;45 Suppl 3:S191 - 5; 9. J Clin Microbiol. 2004 Jun;42(6):2398 - 402; 10. Centers for Disease Control and Prevention. https://www.cdc.gov/hai/settings/ lab/vrsa_lab_search_containment.html; 11. J Infect. 2018 Dec;77(6):489 - 495; 12. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2019 - 2018 Nov 18; 13. HealthJade, https://healthjade.net/vancomycin/; 14. Medscape, https://reference.medscape.com/ drug/firvanq - vancocin - vancomycin - 342573; 15.Combination Antibiotic Treatment of Serious Methicillin - Resistant Staphylococcus aureus Infections, https://www.thieme - connect.com/products/ejournals/pdf/10.1055/s - 0034 - 1396906.pdf ; 16. J Clin Microbiol. 2016 Mar; 54(3): 565 – 568; 17. The description of ALS - 4 and related conclusory statements on ALS - 4 on this slide are based on Aptorum’s internal tests/experimentation and has not yet been verified by clinical trials or third party testing. Vancomycin Lead Project #1 - ALS - 4: Addressing the Shortfall of Vancomycin 9 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

The above diagram summarizes our findings about how ALS - 4 inhibits Staphyloxathin synthesis: • ALS - 4 inhibits a key enzyme in the biosynthesis of Staphyloxanthin with an IC 50 = 20nM. • In the absence of Staphyloxanthin, the bacteria become susceptible to damage by ROS, triggering the usual series of mechanisms by neutrophils that ultimately leads to bacterial cell death. D M S O C o n t r o l A L S - 4 20 0 n M 10 0 n M 5 0 n M 2 5 n M 12 .5 n M 6 .3 n M 3 .1 n M Mechanism of Action: ALS - 4 on Staphyloxathin Synthesis 10 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

• A lethal dose (10 9 CFU) of MRSA was introduced through the tail vein • ALS - 4 was administered orally 30 minutes after infection for twice a day thereafter The combination of ALS - 4 ’s anti - virulence properties together with host immune system, efficacy is still superior. The in vivo data includes rats infected with a lethal dose of MRSA USA300 in a bacteremia model. 55.6% P=0.013 0% Survival (%) Time (d) V e hi c l e ( N = 9 ) ALS - 4 (10mg/kg) (N=9) ALS - 4: Oral Formulation Treatment in an MRSA Survival Study 11 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

• Rats were challenged with a non - lethal dose (10 7 CFU) of MRSA through the tail vein • In order to simulate a more realistic clinical scenario, treatment was introduced 14 - days after infection, where ALS - 4 was administered orally twice a day at 10mg/kg per animal ALS - 4 is shown to greatly reduce organ bacterial count in a bacteremia animal model. C o n t r o l (N=8) 10 4.8 = 63,096 CFU/g p = 0. 0 1 ALS - 4 (10mg/kg) (N=8) 10 2.5 = 316 CFU/g 99.5% reduction K i dn e y b a c t e r i al c o u n t ( C F U / g ) ( l o g 1 0 s c a l e ) ALS - 4: Oral Formulation Treatment in a Non - Lethal Bacteremia Model 12 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

N = 10, CFU per mouse is 6 x 10 7 . All of the treatments were administrated through i.p. 15 hours after infection; (a) Vehicle (b) ALS - 4: 4.5mg/kg (c) Vancomycin: 4.5mg/kg (d) Combo: 4.5mg/kg LM32+4.5mg/kg Vancomycin IMMEDIATE TREATMENT POST LETHAL DOSE N = 10, CFU per mouse is 6x10 7 ALS - 4 at 6.75mg/kg/dose and treatment started 2 hrs post infection twice daily Vancomycin, 4.5 mg/kg/dose and treatment started 18 hrs after infection twice daily DELAYED TREATMENT * S t a tistical si g nifican c e p<0.05 * S t a tistical si g nifican c e p<0.05 ALS - 4: Survival Study of ALS - 4 in Combination of Vancomycin in a Mouse Model Infected with MRSA USA 300 13 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

ALS - 4: Summary of Clinical Study 14 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited • ALS - 4’s first - in - human Phase I trial is a randomized, double - blinded, placebo - controlled, single and multiple ascending dose study designed to evaluate safety, tolerability, and pharmacokinetics of orally administered ALS - 4 in healthy male and female adult volunteers • Clinical parts for both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) have been completed . SAD from 25 mg to 300 mg, MAD from 50 mg to 200 mg twice daily, dosing for 14 days . i. No human subjects were dropped out of the studies and there were no Serious Adverse Events (SAE) observed ii. No relevant clinical changes in respect of vital signs; ECG, clinical laboratory test results and physical examinations were observed compared to the relevant baseline

• ~700 cases of high risk neuroblastoma (NB) patients each year in the US 3 and we estimated EU has 1.5x those cases, c. 1050 high risk NB patients per year • Accounts for ~15% of all cancer - related deaths in the pediatric population 4 • Neuroblastoma is a rare disease and drugs usually qualify for orphan designation subject to FDA • Designated orphan drugs receive 7 years of market exclusivity in US and 10 years of marketing exclusivity in EU • Patents on new indication and reformulation, if granted, will provide up to 20 years of patent exclusivity from the application date in parallel to the market exclusivity SACT - 1 targets, a cancer that develops from nerve cells # 1 Mo s t c ommon type child r en of solid tum o 1 r in US $ 2 . 6 bn V alue of the glo b al neu r obla s t oma 2017 t r e a tment m 2 ar k e t in 3 . 7 % C A GR glo b al neu r obla s t oma (2019 - 2023) t r e a tment mar k 2 e t MARKE T SIZE PREVALENCE ORPHAN DRUG DESIGN A TION 5 1. Pediatr Rev. 2018 Feb;39(2):57 - 67; 2. “Neuroblastoma Market Global Industry Perspective, Comprehensive Analysis, Size, Share, Growth, Trends, and Forecast 2019 – 2023”(2019). MRFR Research. 3. Curr Oncol Rep. 2009 Nov;11(6):431 - 8 4. Paediatr Drugs. 2011 Aug 1;13(4):245 - 55 5. https://www.fda.gov/about - fda/o ffice - special - medical - programs/office - orphan - products - development Lead Project #2 - SACT - 1 (Neuroblastoma): Market Overview 15 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

SACT - 1 when combined with standard of care chemotherapy showed a statistically significant reduction in tumor volume in a xenograft mouse model. ** Unpaired Student’s T - test, p<0.01, n=8 (based on data observed over initial 22 day period of the study, with SOC applied from day 1 to day 15 and SACT - 1 applied from day 1 to day 21) Standard Tx (μM) S A C T - 1 ( µ M ) Synergism Antagonism Synergistic effect observed for SACT - 1 in combination with standard treatment in 2 different neuroblastoma cell lines, as seen in the isobologram SACT - 1: In vivo Study and Synergistic Effect with Chemotherapy 16 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

• A repurposed small molecule drug discovered from our SMART - ACT® platform, which has the potential to help develop drugs with well - established safety profiles in a time - and cost - effective manner • SACT - 1 targeted indication is neuroblastoma, an orphan oncology disease predominantly in children. • In our studies, SACT - 1 has been shown to: - Enhance DNA damage and tumor cell death in vitro - Promote neuroblastoma tumor reduction with standard of care chemotherapy in vivo - Exhibit similar anti - tumor efficacy in vitro across major cancer types, such as colorectal cancer and triple negative breast cancer • Further to the FDA approval of our IND application in 2021, Phase I study on bioavailability/ food effect has been completed. We are on track for submission for Phase Ib/IIa clinical trial in 2022. SACT - 1: Summary of Clinical Study 17 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

INFECTIOUS DISEASES OF UNKNOWN CAUSES REMAIN HIGH Although hospitals have extensive laboratory testing for infectious diseases, it is estimated that aetiology in over 30% of infectious disease cases remained unknown 1 . Current most common clinical diagnostics for infectious disease: Blood Culture Cheap (average $50 per test) but inaccurate Labour intensive Analytically insensitive Trial and error approach and takes up to 5 days to culture at which point the patient may already have worsened in condition Without accurate data, clinicians typically are unable to prescribe appropriate medication or can only apply broad spectrum antibiotics or antivirals that may have limited efficacy on the patient. CONCLUSION A new technology for a rapid, cost - effective, sensitive and unbiased detection for ALL type of pathogens is needed Other technology used in current clinical diagnosis for infectious disease : Other diagnostic technologies including PCR is affordable (average $130 per test) but is biased to “known” specific pathogens only and unable to detect broad spectrum of both known and unknown pathogens. – It is not ready for new emerging infectious diseases (e.g. COVID - 19) 1. Crit Care Med 2012 40(12): 3277 - 3282 Lead Project #3 - RPIDD: Challenges Faced By Infectious Diseases 18 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

Executive Summary OVERVIEW • RPIDD : Next - generation molecular - based diagnostics for “unbiased" detection of any foreign pathogens (virus, bacteria, fungus, parasites) in infected patients using DNA/RNA • <24 hours turnaround time + cost effective • Blood sample and adaptable to others (including swab) • Collaboration with technology from Nobel prize winner Sydney Brenner / A*Star Sg • Patented proprietary technology to prepare and enrich the pathogenic DNA/RNA and deplete the background human host DNA simultaneously + AI analysis TARGET • Next generation technology to transform diagnostic procedures for infectious diseases • T o becom e a fi r s t lin e o f diagnostic s i n lin e o r ahea d o f traditional methods VS CAPABILITIES Based on internal tests, our technology can detect: • A full range of DNA/RNA viruses, bacteria, fungi, parasites, including coronavirus such as COVID19 • Pathogen genes that cause antibiotic/antimicrobial resistance (e.g. MRSA) • Previously unknown and novel mutated pathogens (e.g. new virus) Based on internal tests, our technology can: • REDUCE diagnosis time to 24 hours or less (vs avg. 3 – 5 days using blood culture) • REDUCE c ost of e xisting NG S - based dia g nosis b y mor e than 50% • TARGET TO ACHIEVE analytical specificity >99.99% per pathogen + sensitivity >95% • "Personalized Medicine” approach to infections allowing clinicians to prescribe suitable and targeted treatments at an early stage of patient’s admittance EXISTING METHODS Blood culture : slow (5 days) and inaccurate (c. 80% accuracy) PCR - based diagnosis : biased only to specific pathogens (selective) NGS sequencing : expensive (may cost as much as US$2,000 per test) OUR TECHNOLOGY (based on internal results) x Lower costs: < USD$400 wholesale costs vs >USD$2000 NGS sequencing services x Unbiased and broad range of pathogen detection x <24 hour turnaround time x Unbiased detection of a wide range of foreign pathogens Blood Culture PCR and Film Array Existin g NGS T echnologies Our Technology Rapid No (5 days) Y es ( 1 day) Y es ( 2 days) Y es ( 1 day) Detect unknown pathogens No No (biased & specific to pathogen) Yes Yes Detect antibiotic resistance Y es (limited) Y es (limited) Yes Yes Average Costs USD$100 - 150 per culture / pathogen BUT no broad range detection; specific only > USD$2,000 cost Current < USD$400 cost (target USD$100) OUR SOLUTION: RPIDD (Rapid Pathogen Identification and Detection Device Technology) 19 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

But Why Is Molecular Rapid Diagnostic Testing (mRDT) Currently Not First - line? Therefore, a technology for a rapid, cost - effective, sensitive and unbiased detection for ALL types of pathogens is urgently needed: RPIDD Emerging pathogens and known pathogens with new mutations may not be detected . Current commercially available mRDT are limited in scope for pathogens and antimicrobial resistance marker due to a lack of primers/probes ¹. If a medical laboratory develops its own test using mRDT, the quality of the results will be significantly influenced by the manufacturing source of the reagents used. This limits the flexibility and adds extra costs to the labs. Based on internal results, RPIDD employs an untargeted approach for detection of all known and mutated pathogens , as well as genes that cause antibiotic resistance in a single test. It provides valuable information in a timely manner and the appropriate antimicrobial therapy would be initiated as rapidly as possible. RPIDD is a scalable service integrated in hospitals to support local and regional hospital services for blood - based rapid pathogen diagnostics. RPIDD is an NGS based (Next generation sequencing) molecular diagnostic technology. 1. Karumaa, S.; Karpanoja, P.; Sarkkinen, H. PCR Identification Of Bacteria In Blood Culture Does Not Fit The Daily Workflow Of A Routine Microbiology Laboratory. Journal of Clinical Microbiology 2011, 50 (3), 1031 - 1033. RPIDD Aims to Shift mRDT Methods to First - line Diagnosis 20 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

Proprietary method in DNA/RNA extraction P R OPRI E T A R Y DIAGNOSIS WORKF L OW ( 24 HOURS ) Biofluid collection • ~0.5ml of blood is used in the current generation of method 1 • One - pot DNA & RNA library preparation • Both targeted and untargeted workflows Sample extraction • Host DNA depletion • Microbial DNA/RNA enrichment 2 Next - generation sequencing (NGS) • Tested on Illumina chemistry (NexSeq, HiSeq, MiSeq and iSeq100) • Easy adapted to Nanopore workflow • Compatible with other faster next generation sequencing machines (e.g Nanopore) 3 Secure cloud - based artificial intelligence driven bioinformatics analysis & report generation • Refined workflow for rapid diagnosis of infectious disease 4 6 hrs 8 - 14 hrs <2 hrs P r oprieta r y method P r oprieta r y Software RPIDD Device Workflow Overview 21 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

1.25 copies of DNA/RNA per µl plasma Sensitivity Controls: ZymoBIOMICS Microbial Community Standard, Lentivirus and Seracare AccuSpan recombinant virus Specificity Based on internal results, RPIDD device detected organisms ranging from bacteria, RNA viruses and fungi in ONE TEST • 8 species of bacteria, • 2 species of RNA virus, and • 2 fungal samples were spiked into human plasma All 12 species identified in ONE TEST Analytical Performance: Sensitivity and Specificity 22 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

• Sensitivity and specificity targeted to improve with further v alidation - Sensitivity : Achieved 99.99% - Specificity : Achieved 90%, targeted to exceed 95% (subjected to ongoing clinical validation) • Clinical Validation in progress in Singapore - 12 patients have been enrolled to the scheme - 53 reactions have been analysed as of 31 December 2021 • Further clinical validation planned for 2022 including United States and Singapore. • Further protocol updates to expand the use of RPIDD in different samples are progressing (e.g. Cerebrospinal fluid, nasal swab, saliva). RPIDD : Summary of Clinical Validation 23 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

• Global menopause supplement market is projected to exceed US$50 billion by 2025 1 • NativusWell® is a novel nutraceutical supplement targeting women who are between 45 and 65 years old and experiencing menopausal, perimenopausal and postmenopausal syndromes • Commercialization in the UK, Hong Kong and EU in 2022. Targeted for US market in 2023 subject to registration. • Consists of Chinese yam extract containing DOI, a novel non - hormonal, bioactive compound found to 2 : - Significantly increase estradiol biosynthesis and aromatase expression in an in vitro granulosa cell model and in an in vivo preclinical model - Increase the apparent bone mineral density, bone volume fraction and trabecular thickness in an in vivo preclinical model - Act in a tissue - specific manner. DOI causes upregulation of aromatase, an enzyme involved in the production of estrogen, in the ovary but not in other tissues - Appear to be safe as indicated in both in vitro cellular and in vivo preclinical models NativusWell® (NLS - 2) 1. Grand View Research. Isoflavones Market Size Worth $50.06 Billion By 2025. https://www.grandviewr esear ch.com/press - release/global - isoflavones - market; 2. Sci. Rep. 5, 10179; doi: 10.1038/srep10179 (2015). All conclusory statements on this slide are based on Aptorum’s internal tests/experimentation and has not yet been verified by clinical trials or third party testing. NativusWell®: Executive Summary 24 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

NEW AMBITION IN 2022 - Resistance develops within months or years 3 (varied by the type of cancer and the targeted therapy used) - Some cancer is not responsive to targeted treatments (e.g. RAS - mutated lunch cancer) 4 Next - Generation gene mutation inhibitors Proteolysis - Targeting Chimera (PROTAC) • Work on further improving Cancer Treatment • Lung cancer is by far the leading cause of cancer death among both men and women, making up almost 18% of all cancer deaths in 2020, with over 2 million new cases diagnosed globally 1 . • Targeted therapy (targeting EGFR, ALK and RTKs) is used in biomarker - positive, advanced NSCLC and showed significancy in improving progression free survival of patients 2 . • However, the use of targeted therapy faced limitations: APTORUM’S ONCOLOGY AND AUTOIMMUNE FOCUS IN 2022 • SACT - 1 • DLS - 1 + 2 • DLS - 3 1. Data Source: GLOBOCAN 2020 2. Trends Mol Med. 2019 Mar; 25(3): 185 – 197. doi: 10.1016/j.molmed.2018.12.009 3. Chin J Cancer. 2015; 34: 43. doi: 10.1186/s40880 - 015 - 0047 - 1 3. Prog Tumor Res. 2014;41:62 - 77. doi: 10.1159/000355902. Epub 2014 Feb 17. Targeted Therapy: Still a new hope for Cancer Patient? 25 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

(3) Immunomodulator: Targets inflammatory pathways which have been implicated in the tumorigenesis, angiogenesis, and metastasis of many cancer phenotypes. Can be used for auto - immune and infectious disease, including Lupus and Rheumatoid Arthritis 1st G ene r a tion E r lotinib G efitinib Icotinib etc. Crizotinib Ceritinib Alectinib B r ig a tinib etc. Osimertinib Aumolertinib F u r mone r tinib etc. Lorlatinb E n t r e c tinib BLU - 945 EAI045 CH7233163 etc. R epot r e c tinib Alkotinib Foritinib etc. 2nd G ene r a tion R esistan c e de v eloped R esistan c e de v eloped R esistan c e de v eloped Clinical S tage N e x t gener a tion 3r d G ene r a tion Afatinib Da c omitinib Neratinib EGFR mutated tumour developed mutation against ALK EGFR Mutation ALK Mutation Aptorum’s Focus (2) Targeted protein Degradation Aptorum’s Focus (1) Next - generation inhibitor Aptorum’s Focus Source of Drug: https://adisinsight.springer.com/search Drug resistance is a difficult obstacle to overcome 26 For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome. © Copyright 2022 Aptorum Group Limited

APTORUM GROUP investor.relations@aptorumgroup.com T +852 3953 7700 F +852 3953 7711